This is true for diagnosis, but also more and more relevant in therapeutic approaches, as proven by the development of NTRK inhibitors in infantile fibrosarcoma, mTOR-inhibitors (sirolimus, everolimus) in KHE or in pseudomyogenic hemangioendothelioma, or even PARP inhibitors in clear cell sarcoma of soft tissues. The gene discussed is MTOR; the disease is fibrosarcoma.